<DOC>
	<DOCNO>NCT00968591</DOCNO>
	<brief_summary>This clinical pharmacology research study assess safety pharmacokinetics drug everolimus patient impaired hepatic function compare healthy volunteer .</brief_summary>
	<brief_title>Pharmacokinetics Everolimus Subjects With Hepatic Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>All subject : In good health determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test value ( except value relate hepatic insufficiency ) . Hepatic impaired subject : A ChildPugh Classification score clinically determine Class A , Class B , Class C. Absolute neutrophil count ( ANC ) &gt; 1000 cells/mm3 Hemoglobin &gt; 9 mg/mL Platelet count &gt; 50,000/mm3 screen baseline Serum creatinine â‰¤ 2.0 x ULN Free significant medical disorder unrelated subject 's hepatic disorder All subject : Significant illness , include infection , hospitalization within 4 week prior dose ( hospitalization allow hepatic impaired subject relate liver disease ) . Invasive systemic fungal infection need fully resolve prior study entry . History acute chronic bronchospastic disease ( include asthma chronic obstructive pulmonary disease , treat treat ) . History clinically significant drug allergy ; history atopic allergy ( asthma , urticaria , eczematous dermatitis ) . A known hypersensitivity study drug ( everolimus ) drug similar study drug ( mTOR inhibitor , e.g. , rapamycin temsirolimus ) . Active bleeding last 28 day prior dose , include variceal bleeding . Except hepatic impairment , surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug may jeopardize subject case participation study . Use tobacco within 7 day prior dose study . Consumption alcohol within 3 day prior dose study . Consumption grapefruit , grapefruit juice , Sevilla oranges , starfruit relate food within 7 day prior dose study period . Use drug know affect CYP3A4 PgP , include inhibitor inducer , within 7 day prior dose study . Hepatic impaired subject : Symptoms history Grade 3 4 hepatic encephalopathy within 4 week study entry . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hepatic insufficiency</keyword>
	<keyword>liver disease</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>